<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kefala, A. M.</style></author><author><style face="normal" font="default" size="100%">Fortescue, R.</style></author><author><style face="normal" font="default" size="100%">Alimani, G. S.</style></author><author><style face="normal" font="default" size="100%">Kanavidis, P.</style></author><author><style face="normal" font="default" size="100%">McDonnell, M. J.</style></author><author><style face="normal" font="default" size="100%">Magiorkinis, E</style></author><author><style face="normal" font="default" size="100%">Megremis, S.</style></author><author><style face="normal" font="default" size="100%">Paraskevis, D</style></author><author><style face="normal" font="default" size="100%">Voyiatzaki, C.</style></author><author><style face="normal" font="default" size="100%">Mathioudakis, G. A.</style></author><author><style face="normal" font="default" size="100%">Papageorgiou, E.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Vestbo, J</style></author><author><style face="normal" font="default" size="100%">Beloukas, A.</style></author><author><style face="normal" font="default" size="100%">Mathioudakis, A. G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Prevalence and clinical implications of respiratory viruses in stable chronic obstructive pulmonary disease (COPD) and exacerbations: a systematic review and meta-analysis protocol</style></title><secondary-title><style face="normal" font="default" size="100%">BMJ OpenBMJ OpenBMJ Open</style></secondary-title><alt-title><style face="normal" font="default" size="100%">BMJ open</style></alt-title><short-title><style face="normal" font="default" size="100%">BMJ openBMJ open</style></short-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">*adult thoracic medicine</style></keyword><keyword><style  face="normal" font="default" size="100%">*chronic airways disease</style></keyword><keyword><style  face="normal" font="default" size="100%">*epidemiology</style></keyword><keyword><style  face="normal" font="default" size="100%">*respiratory infections</style></keyword><keyword><style  face="normal" font="default" size="100%">Biotech, Boehringer Ingelheim and grans from Gerolymatos International SA and</style></keyword><keyword><style  face="normal" font="default" size="100%">Capricare, outside the submitted work. JV reports personal fees from Chiesi</style></keyword><keyword><style  face="normal" font="default" size="100%">Menarini/Faes Farma, Sanofi, Mylan/Meda, Biomay, AstraZeneca, GSK, MSD, Asit</style></keyword><keyword><style  face="normal" font="default" size="100%">outside the submitted work. NGP reports personal fees from Novartis, Nutricia, HAL,</style></keyword><keyword><style  face="normal" font="default" size="100%">Pharmaceuticals, Boehringer Ingelheim, Novartis, AstraZeneca, GSK, outside the</style></keyword><keyword><style  face="normal" font="default" size="100%">submitted work. AGM reports grants from Boehringer Ingelheim, outside the submitted</style></keyword><keyword><style  face="normal" font="default" size="100%">work.</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Apr 7</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/04/10</style></edition><volume><style face="normal" font="default" size="100%">10</style></volume><pages><style face="normal" font="default" size="100%">e035640</style></pages><isbn><style face="normal" font="default" size="100%">2044-6055</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Both stable chronic obstructive pulmonary disease (COPD) and acute exacerbations represent leading causes of death, disability and healthcare expenditure. They are complex, heterogeneous and their mechanisms are poorly understood. The role of respiratory viruses has been studied extensively but is still not adequately addressed clinically. Through a rigorous evidence update, we aim to define the prevalence and clinical burden of the different respiratory viruses in stable COPD and exacerbations, and to investigate whether viral load of usual respiratory viruses could be used for diagnosis of exacerbations triggered by viruses, which are currently not diagnosed or treated aetiologically. METHODS AND ANALYSIS: Based on a prospectively registered protocol, we will systematically review the literature using standard methods recommended by the Cochrane Collaboration and the Grading of Recommendations Assessment, Development and Evaluation working group. We will search Medline/PubMed, Excerpta Medica dataBASE (EMBASE), the Cochrane Library, the WHO's Clinical Trials Registry and the proceedings of relevant international conferences on 2 March 2020. We will evaluate: (A) the prevalence of respiratory viruses in stable COPD and exacerbations, (B) differences in the viral loads of respiratory viruses in stable COPD vs exacerbations, to explore whether the viral load of prevalent respiratory viruses could be used as a diagnostic biomarker for exacerbations triggered by viruses and (C) the association between the presence of respiratory viruses and clinical outcomes in stable COPD and in exacerbations. ETHICS AND DISSEMINATION: Ethics approval is not required since no primary data will be collected. Our findings will be presented in national and international scientific conferences and will be published in peer reviewed journals. Respiratory viruses currently represent a lost opportunity to improve the outcomes of both stable COPD and exacerbations. Our work aspires to 'demystify' the prevalence and clinical burden of viruses in stable COPD and exacerbations and to promote clinical and translational research. PROSPERO REGISTRATION NUMBER: CRD42019147658.</style></abstract><accession-num><style face="normal" font="default" size="100%">32269027</style></accession-num><notes><style face="normal" font="default" size="100%">2044-6055Kefala, Anastasia MFortescue, RebeccaAlimani, Gioulinta SKanavidis, ProdromosMcDonnell, Melissa JaneMagiorkinis, EmmanouilMegremis, SpyridonParaskevis, DimitriosVoyiatzaki, ChrysaMathioudakis, Georgios APapageorgiou, EffiePapadopoulos, Nikolaos GVestbo, JørgenBeloukas, ApostolosOrcid: 0000-0001-5639-0528Mathioudakis, Alexander GOrcid: 0000-0002-4675-9616Journal ArticleResearch Support, Non-U.S. Gov'tBMJ Open. 2020 Apr 7;10(4):e035640. doi: 10.1136/bmjopen-2019-035640.</style></notes><custom2><style face="normal" font="default" size="100%">PMC7170624</style></custom2><auth-address><style face="normal" font="default" size="100%">Department of Biomedical Sciences, University of West Attica, Egaleo, Greece.Cochrane Airways, Population Health Research Institute, University of London Saint George's, London, UK.Athens Breath Centre, Athens, Greece.First Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.Department of Respiratory Medicine, Galway University Hospitals, Galway, Ireland.Department of Laboratory Haematology, Sotiria Regional Chest Disease Hospital of Athens, Athens, Greece.Division of Evolution and Genomic Science, The University of Manchester, Manchester, UK.Department of Hygiene, Epidemiology and Medical Statistics, National and Kapodistrian University of Athens, Athens, Greece.Division of Infection, Immunity and Respiratory Medicine, The University of Manchester, Manchester, UK.Allergy Department, 2nd Paediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.North West Lung Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.Division of Infection, Immunity and Respiratory Medicine, The University of Manchester, Manchester, UK alexander.mathioudakis@manchester.ac.uk.</style></auth-address><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record></records></xml>